Age Features of Correlation Between Leptin Level and Severity of Cognitive Impairment in Patients with Chronic Cerebrovascular Insufficiency and Metabolic Syndrome

O.O. Kopchak

Abstract


Objective: to study the possible relationship between leptin level and severity of vascular cognitive impairment in patients with metabolic syndrome and dyscirculatory encephalopathy of various ages; to clarify the nature of correlation between leptin level and components of the metabolic syndrome, as well as between the severity of cognitive impairment and the degree of insulin resistance in examined group of patients in the age aspect. The study included 85 patients with dyscirculatory encephalopathy and metabolic syndrome aged 48 to 85 years. All patients were divided into 3 age groups: 45–59 years — middle age (n = 33), 60–74 years — elderly (n = 32), 75–89 years — senile age (n = 20). The degree of cognitive impairment was assessed using Mini Mental State Examination. All patients underwent clinical and neurological examination, common laboratory tests, determination of leptin level in blood, glucose level and fasting blood insulin, C-reactive protein, instrumental studies. We revealed a significant correlation between leptin level in blood and such components of metabolic syndrome as body mass index (severity of obesity) in patients of middle and elderly age, blood pressure level in patients of middle and senile age, the level of high-density lipoproteins in the group of examined elderly patients. The level of leptin affects the severity of cognitive impairment. Thus, the effect of lowering leptin level on the state of cognitive functions in patients intensified with age: a significant direct correlation between leptin level and the severity of cognitive impairment in examined patients was found in elderly and senile age.


Keywords


cognitive impairment; leptin; metabolic syndrome; age

References


Бачинская Н.Ю. Синдром умеренных когнитивных нарушений / Н.Ю. Бачинская // Нейро News. — 2010. — № 2(1). — С. 12-17.

Березин А.Е. Диагностическая и прогностическая ценность лептина как маркера кардиометаболического риска / А.Е. Березин, А.А. Кремзер // Патологія. — 2012. — № 2(25). — С. 4-9.

Бондарь В.Н. Клинико-патогенетические особенности дислипидемии при артериальной гипертензии в сочетании с метаболическим синдромом / В.Н. Бондарь, Л.Н. Ефременкова, Е.С. Чернышева // Вісник проблем біології і медицини. — 2012. — № 1(94). — С. 43-45.

Дамулин И.В. Дисциркуляторная энцефалопатия: Метод. рекомендации / И.В. Дамулин, В.В. Захаров; под ред. Н.Н. Яхно. — М., 2003. — 32 с.

Лептин и метаболический синдром / А.Е. Чубенко, О.Д. Беляева, О.А. Беркович, Е.И. Баранова // Рос. физиол. журн. — 2010. — № 96(10). — C. 945-965.

Мачерет Е.Л. Современные подходы к дефиниции дисциркуляторной энцефалопатии / Е.Л. Мачерет, И.С. Паламарчук // Зб. наук. праць співробітників КМАПО. — 2003. — Вип. 12, кн. 1. — С. 591-605.

Метаболический синдром — болезнь хронического низкоинтенсивного системного воспаления? / М.С. Расин, А.В. Лавренко, О.А. Борзых, С.М. Расин, И.П. Кайдашев // Український терапевтичний журнал. — 2011. — № 4. — С. 56-62.

Расін О.М. Молекулярні механізми протизапальної дії глітазонів та статинів: роль PPARγ / О.М. Расін, І.П. Кайдашев, М.С. Расін // Міжнародний ендокринологічний журнал. — 2007. — № 6(12). — С. 71-76.

Роль инсулинорезистентности в развитии дислипидемии у людей пожилого возраста / О.В. Коркушко, В.Б. Шатило, В.П. Чижова, В.А. Ищук // Пробл. старения и долголетия. — 2009. — № 4. — С. 393-402.

Adipokines and aging / Y. Arai, M. Takayama, Y. Abe, N. Hirose // Journal of Atherosclerosis and Тhrombosis. — 2011. — № 18. — P. 1-6.

Betsy B. The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids / B. Betsy, B.B. Dokken // Diabetes Spectrum. — 2008. — № 2(3). — P. 160-165.

Cardiovascular Death and the Metabolic Syndrome. Role of adiposity-signaling hormones and inflammatory markers / C. Langenberg, J. Bergstrom, C. Scheidt-Nave [et al.] // Diabetes Care. — 2006. — Vol. 29. — P. 1363-1369.

Eckel R.H. The metabolic syndrome / R.H. Eckel, S.M. Grundy, P.Z. Zimmet // Lancet. — 2005. — Vol. 365. — P. 1415-1428.

Folstein M. Mini-mental state: a practical method for grading the cognitive state of patients for the clinical / M. Folstein, S. Folstein, P.R. McHugh // J. Psychiatr. Res. — 1975. — № 12. — P. 189-198.

Genetic Variation Within a Metabolic Motif in the Chromogranin. A Promoter: Pleiotropic Influence on Cardiometabolic Risk Traits in Twins / F. Rao, S. Chiron, Z. Wei [et al.] // Am. J. Hypertens. — 2012. — Vol. 25(1). — Р. 29-40.

Harmonizing the metabolic syndrome. A joint interim statement of the International diabetes federation task force on epidemiology and prevention, National heart, lung, and blood institute, American heart association, World heart federation, International atherosclerosis society, and International association for the study of obesity / K.G.M. Alberti, R.H. Eckel, S.M. Grundy [et al.] // Circulation. — 2009. — Vol. 120. — P. 1640-1645.

Harvey J. Leptin: a diverse regulator of neuronal function / J. Harvey // J. Neurochem. — 2007. — Vol. 100. — P. 307-313.

Leptin: A Novel Therapeutic Strategy for Alzheimer’s Disease / N. Tezapsidisa, J.M. Johnstona, M.A. Smith [et al.] // J. Alzheimers. Dis. — 2009. — № 16(4). — P. 731-740.

Leptin promotes adult hippocampal neurogenesis in vivo and in vitro / J.C. Garza, M. Guo, W. Zhang, X.Y. Lu // J. Biol. Chem. — 2008. — Vol. 283. — P. 18238-18247.

Metabolic syndrome as a risk factor for neurological disorders / А.А. Farooqui, T. Farooqui, F. Panza, V. Frisardi // Cell. Mol. Life Sci. — 2012. — Vol. 69(5). — Р. 741-62.

Paulus K. Central nervous effects of leptin and insulin on hippocampal leptin and insulin receptor expression following a learning task in wistar rats / K. Paulus, C. Schulz, H. Lehnert // Neuropsychobiology. — 2005. — Vol. 51. — P. 100-106.

Ronti T. The endocrine function of adipose tissue: an update / T. Ronti, G. Lupattelli, E. Monnarino // Clin. Endocrinol. — 2006. — Vol. 64. — Р. 355-365.

Toda C. Mechanism of dysregulated energy homeostasis in metabolic syndrome / C. Toda // Nihon. Rinsho. — 2011. — Vol. 69(1). — Р. 133-137.

Unger R.H. Diseases of liporegulation: new perspective on obesity and relateddisorders / R.H. Unger, L. Orci // FASEB J. — 2001. — № 15. — P. 312-321.

Wiwanitkit S. Insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein and metabolic syndrome / S. Wiwa-nitkit, V. Wiwanitkit // Ann. Thorac. Med. — 2011. — № 6(4). — Р. 243.

Younus S. Biomarkers associated with cardiometabolic risk in obesity / S. Younus, G. Rodgers // Am. Heart Hosp. J. — 2011. — № 9(1). — Р. 28-32.




DOI: https://doi.org/10.22141/2224-0713.1.63.2014.80439

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru